HomeCompareGILD vs NOW

GILD vs NOW: Dividend Comparison 2026

GILD yields 2.34% · NOW yields 1.91%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GILD wins by $6.7K in total portfolio value
10 years
GILD
GILD
● Live price
2.34%
Share price
$136.34
Annual div
$3.19
5Y div CAGR
17.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.1K
Annual income
$1,614.90
Full GILD calculator →
NOW
NOW
● Live price
1.91%
Share price
$104.97
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.5K
Annual income
$215.52
Full NOW calculator →

Portfolio growth — GILD vs NOW

📍 GILD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGILDNOW
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GILD + NOW cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GILD pays
NOW pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GILD
Annual income on $10K today (after 15% tax)
$198.88/yr
After 10yr DRIP, annual income (after tax)
$1,372.67/yr
NOW
Annual income on $10K today (after 15% tax)
$161.95/yr
After 10yr DRIP, annual income (after tax)
$183.19/yr
At 15% tax rate, GILD beats the other by $1,189.47/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GILD + NOW for your $10,000?

GILD: 50%NOW: 50%
100% NOW50/50100% GILD
Portfolio after 10yr
$25.8K
Annual income
$915.21/yr
Blended yield
3.55%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on NOW right now

GILD
Analyst Ratings
37
Buy
20
Hold
1
Sell
Consensus: Buy
Price Target
$158.71
+16.4% upside vs current
Range: $105.00 — $180.00
Altman Z
4.1
Piotroski
8/9
NOW
Analyst Ratings
58
Buy
8
Hold
1
Sell
Consensus: Buy
Price Target
$196.29
+87.0% upside vs current
Range: $115.00 — $263.00
Altman Z
6.1
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GILD buys
0
NOW buys
14
PoliticianChamberTickerTypeAmountDate
Charles J. "Chuck" Fleischmann🏢 House$NOW▲ Buy$1,001 - $15,0002026-02-20
Byron Donalds🏢 House$NOW▲ Buy$1,001 - $15,0002026-02-10
Byron Donalds🏢 House$NOW▲ Buy$1,001 - $15,0002026-02-10
Tony Wied🏢 House$NOW▲ Buy$15,001 - $50,0002026-02-04
Josh Gottheimer🏢 House$NOW▼ Sell$1,001 - $15,0002026-01-30
Markwayne Mullin🏛 Senate$NOW▲ Buy$15,001 - $50,0002025-12-29
Markwayne Mullin🏛 Senate$NOW▲ Buy$15,001 - $50,0002025-12-29
Josh Gottheimer🏢 House$NOW▼ Sell$1,001 - $15,0002025-12-17
Julie Johnson🏢 House$NOW▼ Sell$1,001 - $15,0002025-12-09
Michael McCaul🏢 House$NOW▲ Buy$1,001 - $15,0002025-10-31
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGILDNOW
Forward yield2.34%1.91%
Annual dividend / share$3.19$2.00
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR17.3%0%
Portfolio after 10y$29.1K$22.5K
Annual income after 10y$1,614.90$215.52
Total dividends collected$7.6K$2.0K
Payment frequencyquarterlyquarterly
SectorHealthcareStock
Analyst consensusBuyBuy
Analyst price target$158.71$196.29

Year-by-year: GILD vs NOW ($10,000, DRIP)

YearGILD PortfolioGILD Income/yrNOW PortfolioNOW Income/yrGap
1← crossover$10,974$274.45$10,891$190.53+$83.00GILD
2$12,073$330.19$11,847$193.92+$226.00GILD
3$13,316$398.20$12,873$197.15+$443.00GILD
4$14,730$481.49$13,975$200.22+$755.00GILD
5$16,345$583.87$15,156$203.13+$1.2KGILD
6$18,199$710.26$16,423$205.89+$1.8KGILD
7$20,340$866.96$17,781$208.50+$2.6KGILD
8$22,826$1,062.22$19,236$210.97+$3.6KGILD
9$25,731$1,306.80$20,796$213.31+$4.9KGILD
10$29,147$1,614.90$22,468$215.52+$6.7KGILD

GILD vs NOW: Complete Analysis 2026

GILDHealthcare

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

Full GILD Calculator →

NOWStock

ServiceNow, Inc. provides enterprise cloud computing solutions that defines, structures, consolidates, manages, and automates services for enterprises worldwide. It operates the Now platform for workflow automation, artificial intelligence, machine learning, robotic process automation, performance analytics, electronic service catalogs and portals, configuration management systems, data benchmarking, encryption, and collaboration and development tools. The company also provides information technology (IT) service management applications; IT service management product suite for enterprise's employees, customers, and partners; IT business management product suite; IT operations management product that connects a customer's physical and cloud-based IT infrastructure; IT Asset Management to automate IT asset lifecycles; and security operations that connects with internal and third party. In addition, it offers governance, risk, and compliance product to manage risk and resilience; human resources, legal, and workplace service delivery products; safe workplace applications; customer service management product; and field service management applications. Further, it provides App Engine product; IntegrationHub enables application to extend workflows; and professional, industry solutions, and customer support services. It serves government, financial services, healthcare, telecommunications, manufacturing, IT services, technology, oil and gas, education, and consumer products through direct sales team and resale partners. It has a strategic partnership with Celonis to help customers identify and prioritize processes that are suitable for automation. The company was formerly known as Service-now.com and changed its name to ServiceNow, Inc. in May 2012. The company was founded in 2004 and is headquartered in Santa Clara, California.

Full NOW Calculator →
📬

Get this GILD vs NOW comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GILD vs SCHDGILD vs JEPIGILD vs OGILD vs KOGILD vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.